ExpressCells
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $1M
Investors
- 8
About ExpressCells
Based in Philadelphia, US, and founded in 2018, ExpressCells operates as a biotechnology company that creates knock-in cell lines for biological research and uses CRISPR plus a proprietary genetic vector system to create custom cells for research. ExpressCells assists in making precise cuts into a cell's genome and then uses a patent-pending plasmid system to insert new genes into the cell to create a genetically altered cell line, allowing researchers to visualize proteins and organelles inside the cell.
Who invested in ExpressCells
8 investors across 2 rounds
See all investors in ExpressCells
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ExpressCells
Who invested in ExpressCells?
ExpressCells has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ExpressCells raised?
ExpressCells has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ExpressCells last raise money?
ExpressCells's most recent round on record is a Series A, in Apr 2021.
What does ExpressCells do?
Based in Philadelphia, US, and founded in 2018, ExpressCells operates as a biotechnology company that creates knock-in cell lines for biological research and uses CRISPR plus a proprietary genetic vector system to create custom cells for research.
Where is ExpressCells headquartered?
ExpressCells is headquartered in Philadelphia, US.
Which VCs invest in companies like ExpressCells?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ExpressCells's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ExpressCells? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.